Search results for "Azoles"

showing 10 items of 899 documents

Effect of histamine on the longitudinal and circular muscle of the oestrogen dominated rat uterus.

1993

The response of the longitudinal and circular myometrial strips to histamine was studied in oestrogen-treated rats. Histamine produced a dose-related inhibitory response in KCl-contracted longitudinal and circular uterine strips. Histamine was equipotent in producing the relaxant response but the maximal effect achieved in the longitudinal muscle was higher than the circular one. Ranitidine antagonized the histamine-induced relaxation with a similar dose ratio in both longitudinal and circular strips. Clemizole and reserpine treatment did not produce any modification of the dose-response curve to histamine. In the longitudinal and circular strips which were not preconstricted by KCl, neithe…

medicine.medical_specialtyReserpinePyridinesMuscle RelaxationImmunologyUterusBiologyIn Vitro TechniquesToxicologyInhibitory postsynaptic potentialRanitidinePotassium ChlorideRanitidineHistamine Agonistschemistry.chemical_compoundUterine ContractionInternal medicinemedicineAnimalsPharmacology (medical)Receptors Histamine H2Rats WistarPharmacologyUterusEstrogensMuscle SmoothReserpineClemizoleRatsmedicine.anatomical_structureEndocrinologychemistryIn uteroBenzimidazolesFemalemedicine.symptomHistaminemedicine.drugMuscle contractionHistamineAgents and actions
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental s…

2016

We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss them mechanistically in the context of expression and other preclinical data.Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. Hypertension is the most frequently observed adverse event, but has a similar incidence with mirabegron and placebo. Nevertheless, severe uncontrolled hypertension has become a contraindication for use of mirabegron based on observation o…

medicine.medical_specialtySide effect030232 urology & nephrologyUrologyContext (language use)Adrenergic beta-3 Receptor AgonistsBenzoates03 medical and health sciences0302 clinical medicineSolabegronmedicineAnimalsHumansPharmacology (medical)Adverse effectAniline Compoundsbusiness.industryUrinary Bladder OveractiveGene Expression ProfilingBiphenyl CompoundsGeneral MedicineBiphenyl compoundThiazolesTolerability030220 oncology & carcinogenesisAnesthesiaReceptors Adrenergic beta-3AcetanilidesTolterodinebusinessMirabegronmedicine.drugExpert opinion on drug safety
researchProduct

Intracoronary Infusion of Thioflavin-S to Study Microvascular Obstruction in a Model of Myocardial Infarction

2015

Abstract Introduction and objectives Microvascular obstruction exerts deleterious effects after myocardial infarction. To elucidate the role of ischemia-reperfusion injury on the occurrence and dynamics of microvascular obstruction, we performed a preliminary methodological study to accurately define this process in an in vivo model. Methods Myocardial infarction was induced in swine by means of 90-min of occlusion of the mid left anterior descending coronary artery using angioplasty balloons . Intracoronary infusion of thioflavin-S was applied and compared with traditional intra-aortic or intraventricular instillation. The left anterior descending coronary artery perfused area and microvas…

medicine.medical_specialtySwineUltraviolet RaysSus scrofaMyocardial InfarctionLumen (anatomy)Myocardial Reperfusion InjuryAnterior Descending Coronary ArteryCoronary AngiographyBalloonMicrocirculationCoronary CirculationInternal medicineOcclusionPhotographymedicineAnimalsInfusions Intra-ArterialBenzothiazolesMyocardial infarctionFluorescent Dyesbusiness.industryMicrocirculationGeneral Medicinemedicine.diseaseCoronary VesselsDisease Models AnimalThiazolesCoronary OcclusionCoronary occlusionMicrovesselsCardiologybusinessPerfusionRevista Española de Cardiología (English Edition)
researchProduct

Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner – A quantitative in vitro gene expression analy…

2010

Bisphosphonates are widely used in the clinical treatment of bone diseases with increased bone resorption. In terms of side effects, they are known to be associated with osteonecrosis of the jaw (BONJ). There are two groups of bisphosphonates: the nitrogen-containing bisphosphonates, e.g. zoledronate and ibandronate, and the non-nitrogen-containing bisphosphonates, e.g. clodronate. Their impact on bone metabolism seems to differ. The objective of this study was to compare the osteogenic differentiation potency of these two pharmacologic groups. Human osteoblasts were stimulated with zoledronate and ibandronate at concentrations of 5×10(-5) M, 5×10(-6) M and 5×10(-7) M over the experimental …

medicine.medical_specialtyTime Factorsmedicine.medical_treatmentOsteocalcinCell Culture TechniquesCore Binding Factor Alpha 1 SubunitZoledronic AcidIbandronic acidBone remodelingInternal medicineHumansMedicineIbandronic AcidHomeodomain ProteinsMSX1 Transcription FactorOsteoblastsBone Density Conservation AgentsDiphosphonatesDose-Response Relationship DrugbiologyReverse Transcriptase Polymerase Chain Reactionbusiness.industryImidazolesCell DifferentiationOsteoblastDLX5BisphosphonateRUNX2Zoledronic acidmedicine.anatomical_structureEndocrinologyGene Expression RegulationOtorhinolaryngologyOsteocalcinbiology.proteinSurgeryBone RemodelingClodronic AcidOral SurgerybusinessBiomarkersTranscription Factorsmedicine.drugJournal of Cranio-Maxillofacial Surgery
researchProduct

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct

Progestogens stimulate prostacyclin production by human endothelial cells.

2005

BACKGROUND: The effects of progestogens on endothelial physiology are poorly studied. Prostacyclin is a potent vasodilator synthesized by two isoforms of cyclooxygenase (COX) in endothelium. We examined the effects of two clinically used progestogens, progesterone and medroxyprogesterone acetate (MPA), on prostacyclin production by cultured human umbilical vein endothelial cells (HUVEC) and the possible role of progesterone receptors and both COX enzymes. METHODS: Cells were exposed to 1-100 nmol/l of either progesterone or MPA and prostacyclin production was measured in culture medium. RESULTS: Both progestogens significantly increased prostacyclin release in a time- and dose-dependent man…

medicine.medical_specialtyUmbilical VeinsEndotheliumProstacyclinMedroxyprogesterone AcetateUmbilical veinInternal medicineProgesterone receptormedicineMedroxyprogesterone acetateHumansCyclooxygenase InhibitorsReceptorCells CulturedNitrobenzenesProgesteroneSulfonamidesbiologyCyclooxygenase 2 InhibitorsDose-Response Relationship DrugEstradiolRehabilitationObstetrics and GynecologyEndothelial CellsMembrane ProteinsEpoprostenolEndothelial stem cellMifepristoneEndocrinologymedicine.anatomical_structureReproductive MedicineCyclooxygenase 2Prostaglandin-Endoperoxide Synthasescardiovascular systembiology.proteinCyclooxygenase 1PyrazolesCyclooxygenaseEndothelium VascularProgestinsReceptors Progesteronemedicine.drugHuman reproduction (Oxford, England)
researchProduct

New frontiers in anticoagulation: non vitamin-K oral anticoagulants in stroke prevention

2016

ABSTRACTIntroduction: Non vitamin-K oral anticoagulants (NOACs) are direct and specific inhibitors of the coagulation factors IIa (dabigatran) and Xa (apixaban, rivaroxaban, edoxaban) which share many pharmacokinetic properties. However, indications are lacking regarding the use of NOACs during thrombolysis, surgery and bleeding events.Areas covered: In this paper, the authors retrospectively analyzed the relevant literature on the NOACs using the PubMed and Google Scholar databases.Expert commentary: Although warfarin is effective in cardioembolic stroke prevention, easier handling and more favorable risk-benefit profile often render NOACs a more preferable therapy choice for neurologists.…

medicine.medical_specialtyVitamin KPyridonesaspirinmedicine.medical_treatmentAdministration Oral030204 cardiovascular system & hematologyDabigatranAnticoagulation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEdoxabanmedicineHumansatrial fibrillationPharmacology (medical)030212 general & internal medicineIntensive care medicineRivaroxabanAspirinbusiness.industryGeneral Neurosciencenon vitamin-K oral anticoagulantWarfarinAnticoagulantsreverse therapyAtrial fibrillationThrombolysismedicine.diseasemeasure of monitoringStrokewarfarinchemistryAnesthesiaPyrazolesApixabanstroke preventionNeurology (clinical)businessmedicine.drugExpert Review of Neurotherapeutics
researchProduct

Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants

2010

An increasing number of patients receive anticoagulant therapy to prevent and treat arterial or venous thromboembolism. The major complication of anticoagulant therapy is the increase of the individual bleeding risk. All anticoagulant drugs can cause haemorrhages, that can sometimes be life-threatening. Although heparins and the vitamin K antagonists have been the most widely used anticoagulants for decades, the correct management of bleeding complications associated with these agents has been poorly studied. More recently, new anticoagulant drugs, both parenteral and oral, have been approved for clinical use. Currently, none of these new agents has a specific antidote, and little advise ca…

medicine.medical_specialtyVitamin Kmedicine.drug_classMorpholinesHemorrhageFactor VIIaThiophenesVitamin kFondaparinuxDabigatranRivaroxabanPolysaccharidesRisk FactorsDrug DiscoverymedicineHumansProtaminesIntensive care medicinePharmacologyRivaroxabanHeparinbusiness.industryAntithrombinAnticoagulantAnticoagulantsHeparinRecombinant ProteinsDabigatranFondaparinuxbeta-AlanineBenzimidazolesComplicationbusinessBleeding anticoagulantsmedicine.drugCurrent Pharmaceutical Design
researchProduct

Gastrointestinal disorders and dabigatran.

2012

Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few. Within recent years, a promising new oral anticoagulant, the direct thrombin inhibitor dabigatran etexilate (dabigatran) successfully underwent clinical development and has emerged as an alternative to vitamin K antagonists according to a variety of recently revised and updated international guidelines referring to the indication of stroke prevention in atrial fibrillation. Considering the intensive clinical u…

medicine.medical_specialtybusiness.industryPyridinesGastroenterologyAnticoagulantsAtrial fibrillationVitamin kmedicine.diseaseDabigatranDabigatranStrokeDirect thrombin inhibitorStroke preventionAnesthesiaAtrial FibrillationmedicineOral anticoagulantHumansBenzimidazolesDyspepsiabusinessIntensive care medicineStrokeVenous thromboembolismmedicine.drugScandinavian journal of gastroenterology
researchProduct